Fig 1: Activity of the cystine-glutamate antiporter SLC7A11 modulates intracellular redox, cell death, and type 2 signature protein expression.(A) Inhibition of SLC7A11 activity by erastin lowers intracellular GSH and the GSH:GSSG ratio (n = 6). (B) This decrease in GSH:GSSG is accompanied by increased expression of 15LO1 (n = 4). (C) The decreased GSH:GSSG increases LDH release, consistent with activation of oxidatively driven cell death (n = 6). (D) Representative Western blot of intracellular and secreted type 2 signature markers following SLC7A11 chemical inhibition with erastin for 24 hours (n = 3–4). (E) Densitometry results showing increases in intracellular periostin (POSTN), CCL26, and iNOS following treatment with erastin (n = 3–4). (F) Densitometry results showing parallel fold-change increases in basilar secretion of POSTN and CCL26, with increased apical secretion of MUC5AC protein following treatment with erastin (n = 4). Matched-pair analysis following log transformation was used to compare the conditions.